189339-69-3

Upstream product

• 504-15-4 orcinol 
• 2905-23-9 2-chlorophenylsulfonyl chloride 
• 6153-39-5 5-Methylresorcinol monohydrate 

Downstream Products

• 189340-39-4 2-Chlorobenzenesulfonic acid 3-[[3-N-(tert-butoxycarbonyl)amino]propoxy]-5-methylphenyl ester 
• 189339-70-6 2-Chlorobenzenesulfonic acid 3-[[N-(tert-butoxycarbonyl)piperidin-4-yl]methoxy]-5-methylphenyl ester 
• 189339-76-2 2-Chlorobenzenesulfonic acid 3-[[N-(tert-butoxycarbonyl)piperidin-3-yl]methoxy]-5-methylphenyl ester 
• 193096-34-3 2-Chlorobenzenesulfonic acid3-[3-cyanopropoxy]-5-methylphenylester 
• 193096-51-4 2-chlorobenzenesulfonic acid 3-[5-cyanopentyloxy]-5-methylphenyl ester 
• 193096-41-2 2-chlorobenzenesulfonic acid 3-[(4-cyanophenyl)methoxy]-5-methylphenyl ester 
• 197959-51-6 1-(2-chlorophenylsulfonyloxy)-3-(3-benzyloxy)propoxy-5-methylbenzene 
• 193095-48-6 2-chlorobenzenesulfonic acid 3-[(3-cyanophenyl)methoxy]-5-methylphenyl ester 
• 189340-42-9 2-Chlorobenzenesulfonic acid 3-[[4-(N-tert-butoxycarbonyl)amino]butoxy]-5-methylphenyl ester 
• 197959-52-7 3-[3-(2-chlorophenylsulfonyloxy)-5-methylphenoxy]propanol 
• 197959-53-8 3-[3-(2-chlorophenylsulfonyloxy)-5-methylphenoxy]propionaldehyde 

Relevant academic research and scientific papers

AMIDINOHYDRAZONES AS PROTEASE INHIBITORS

Amidino and benzamidino compounds, including compounds of the formula: I wherein R1-R4, R6-R9, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I.

Aminoguanidines and alkoxyguanidines as protease inhibitors

Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: wherein X is O or NR9and R114 R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and mare set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

Amidinohydrazones as guanidine bioisosteres: Application to a new class of potent, selective and orally bioavailable, non-amide-based small-molecule thrombin inhibitors

We describe a new class of potent, non-amide-based small molecule thrombin inhibitors in which an amidinohydrazone is used as a guanidine bioisostere on a non-peptide scaffold. Compound 4 exhibits nM inhibition of thrombin, is selective for thrombin, and

Structure-activity and crystallographic analysis of a new class of non- amide-based thrombin inhibitor

The structure-activity relationships of a novel series of non-amide- based thrombin inhibitors are described. Exploration of the P2 and the aryl binding region for this series has identified optimal groups for achieving nanomolar potency. The binding modes of these optimal groups have been confirmed by X-ray structural analysis.

Amidino protease inhibitors

Amidino and benzamidino compounds, including compounds of the formula: wherein R1-R4, R6-R9, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit a number of proteolytic enzymes are described. Also described are methods for preparing the compounds of Formula I.

AMIDINOHYDRAZONES AS PROTEASE INHIBITORS

Amidino and benzamidino compounds, including compounds of the formula: STR1 wherein R 1-R 4, R 6-R 9, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I.

GUANIDINO PROTEASE INHIBITORS

Compounds of the formula: STR1 wherein R 1--R 4, R. sup.7--R 8, R a, R b, R c, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit a number of proteolytic enzymes are described. Also described are methods for preparing the compounds of Formula I.